Navigation Links
Nabriva Therapeutics Announces Appointment of New CEO
Date:7/2/2008

VIENNA, Austria, July 3 /PRNewswire/ -- Nabriva Therapeutics, a specialist in antibiotics development, announces that Dr. George Golumbeski has been appointed as Chief Executive Officer of the Company.

Dr. Golumbeski brings to the team nearly twenty years of industry experience serving most recently as Vice President of Business Development, Licensing & Strategy for the oncology business unit at Novartis. In this position he was responsible for the full array of business development activities leading several transactions which have resulted in projects currently in Phase III studies. While at Novartis, Dr. Golumbeski also served as a member of the Executive Committee which oversees overall oncology business performance. Prior to his tenure at Novartis, he led transactions which have resulted in two products that have been approved or are in registration in the US and the EU.

"I am excited to join Nabriva at this important stage of its growth. The Company's highly differentiated compounds have the potential to address the significant need for new classes of effective antibiotics. Furthermore, the team at Nabriva is highly experienced with a deep understanding and enthusiasm for the development of novel antibiotics," commented Dr. Golumbeski.

David Chiswell, Chair of the Supervisory Board, added, "We are pleased to welcome George to the team. His leadership skills combined with his strategic and business development insight will help position Nabriva as one of the leading specialist companies in antibiotics development."

About Nabriva Therapeutics:

Headquartered in Vienna, Nabriva Therapeutics is engaged in the discovery and development of innovative antibacterial agents addressing unmet medical need in the hospital and community setting. The company has two compounds currently in clinical trials and expects to have a third compound enter clinical trials later this year. The lead compound, BC-3205, is a parenterally and orall
'/>"/>

SOURCE Nabriva Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors
2. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
3. Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBCs Drug Discovery & Development of Innovative Therapeutics Conference
4. Tobira Therapeutics Inc. Announces Senior Management Team
5. Duska Therapeutics Obtains Standard & Poors Listing
6. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
7. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
8. Sirion Therapeutics Announces FDA Approval of Durezol(TM) for Treatment of Postoperative Ocular Inflammation and Pain
9. Commercial Launch of Lexiscan(TM) (Regadenoson) Injection Triggers $10 Million Milestone Payment from TPG-Axon Capital to CV Therapeutics
10. Barrier Therapeutics to Merge Into Stiefel Laboratories
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... 2015 Lighthouse Information Systems, Inc., ... in California, Oregon, Washington and clients across the ... and Acquisition (M&A) Integration Services offering, effective immediately. ... Services and M&A Integration Practice Leader at Lighthouse, ... majority of M&A initiatives fail to achieve their ...
(Date:3/30/2015)... , March 30, 2015  Multiple new research abstracts ... several important health factors. From their impact on colon ... positive effect on both gut health and vascular health, ... detail our latest understanding of walnuts, inner workings. Running ... , this annual meeting attracts an international audience ...
(Date:3/30/2015)... NEW BRUNSWICK, N.J. , March 30, 2015 /PRNewswire-USNewswire/ ... research and innovation projects in the state of ... to its next round of grant funding, announced ... existing New Jersey Health Foundation Research Grants program, an ... to $35,000 each to fund early stage research projects ...
(Date:3/30/2015)... OTTAWA , March 30, 2015 /CNW/ - A ... today on the salaries and demographic profiles of new ... "Opening the Door – Building Careers for New Grads ... Canada,s Research-Based Pharmaceutical Companies (Rx&D) and features ... federal Career Focus wage subsidy program from 2013 to ...
Breaking Biology Technology:Lighthouse Information Systems, Inc., Announces Addition of M&A Integration Services 2New Findings Support the Benefits of Eating Walnuts on Overall Health 2New Findings Support the Benefits of Eating Walnuts on Overall Health 3New Findings Support the Benefits of Eating Walnuts on Overall Health 4New Jersey Health Foundation Announces An Additional $1 Million To Fund Innovation and Research Grants in New Jersey 2New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 2New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 3New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 4
... Limited (LSE:SHP, NASDAQ: SHPGY), the global specialty,biopharmaceutical company, will ... Results press release will be issued at: ... Investor meeting and conference call time: 14:30 BST ... conference call:, Angus Russell, Chief Executive Officer, Graham ...
... July 3 Cellectis SA today,announced the signature ... use of Cellectis, patents covering certain uses of ... including,the development of fully human monoclonal antibodies. As ... of 12,450,000$ from Regeneron.,In addition, Regeneron will invest ...
... Inc. and Isis,Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... and OncoGenex has elected to independently,develop its lead ... solely responsible for all future development activities,costs and ... longer be,responsible for funding 35% of development costs, ...
Cached Biology Technology:Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008 2Cellectis and Regeneron Sign an Agreement Over the use of Homologous Recombination Technology 2OncoGenex increases economic interest in lead cancer drug OGX-011 2OncoGenex increases economic interest in lead cancer drug OGX-011 3OncoGenex increases economic interest in lead cancer drug OGX-011 4
(Date:3/20/2015)... Mar. 19, 2015 Research and Markets ( ... Geometry - Global Strategic Business Report" report to their ... Hand Geometry in US$ Thousands. The report provides separate comprehensive ... Japan , Europe , ... and Rest of World. Annual estimates and forecasts ...
(Date:3/17/2015)... , March 17, 2015 MedNet ... specializing in clinical study management systems, is pleased ... attendance at ARENA,s Outsourcing in Clinical Trials Southeast ... event provides an excellent forum for MedNet to ... and affordable software-as-a-service (SaaS) eClinical technology platform. ...
(Date:3/12/2015)... 12, 2015 The mascots of the Atlantic ... part of Wake Forest Baptist Medical Center. They stopped ... 2015 ACC Men,s Basketball Tournament. Young patients enjoyed bonding ... getting their autographs. Brenner Children,s Hospital is ... the only children,s hospital in northwest North ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... Northwestern Medicine scientists have identified a component ... cells, allowing the virus to rapidly and successfully ... Led by Gregory Smith, associate professor in immunology ... Medicine, researchers found that viral protein 1-2, or ...
... carry an abundance of bacteria on their surfaces, not all ... the variety of these non-pathogenic bacteria, scientists report that these ... cultivation practices. The results are published March 27 in the ... and Noah Fierer at the University of Colorado, Boulder. ...
... of Medicine at Mount Sinai is leading an international team ... to gain a better understanding of Alzheimer,s disease (AD). As ... Noggle, PhD, the NYSCF Charles Evans Senior Research Fellow ... Cell Foundation (NYSCF),s laboratory in Manhattan. Dr. Gandy heads ...
Cached Biology News:How herpesvirus invades nervous system 2Mount Sinai leads global program using stem cells to accelerate cures for Alzheimer's disease 2
... LiCl precipitation offers major advantages over other RNA ... DNA, protein or carbohydrates. It is the method ... cDNA synthesis from RNA preparations. Note, LiCl precipitation ... RNA isolations. If the RNA is to be ...
...
...
The Captivate Disposable Sample Chamber is designed for use with the Captivate magnetic yoke assembly (C-24700) and can be used with our Captivate ferrofluid conjugates (C-21473 C-21474 C-21476) or ...
Biology Products: